Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 151 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Mikhailidis, Dimitri P [Clear All Filters]
Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report..
Curr Vasc Pharmacol. 12(3), 505-11.
(2014). Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness..
J Am Soc Hypertens. 8(2), 74-82.
(2014). Metabolic syndrome and non-cardiac vascular diseases: an update from human studies..
Curr Pharm Des. 20(31), 4944-52.
(2014). Novel data on the pathogenesis of atherosclerosis, treatment targets, and new therapeutic interventions in lipid-related cardiovascular risk factors..
Curr Pharm Des. 20(40), 6215-9.
(2014). Peripheral artery disease in patients with type 2 diabetes..
J Diabetes Complications. 28(6), 912.
(2014). Reaching hypertriglyceridemia goals..
Curr Med Res Opin. 30(3), 391-3.
(2014). The role of statins in the treatment of type 2 diabetes mellitus: an update..
Curr Pharm Des. 20(22), 3665-74.
(2014). Should we expand the concept of coronary heart disease equivalents?.
Curr Opin Cardiol. 29(4), 389-95.
(2014). Subclinical Cushing's syndrome and cardiovascular disease..
Lancet Diabetes Endocrinol. 2(5), 361.
(2014). Therapy: Caloric and fat intake in statin users..
Nat Rev Endocrinol. 10(8), 450-1.
(2014). Uric acid, chronic kidney disease and type 2 diabetes: a cluster of vascular risk factors..
J Diabetes Complications. 28(2), 122-3.
(2014). 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?.
Metabolism. 62(1), 21-33.
(2013). Alcohol consumption and the heart..
Int J Cardiol. 168(4), 4319.
(2013). Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property"..
Dig Liver Dis. 45(1), 82-3.
(2013). Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review..
Curr Med Res Opin. 29(10), 1263-74.
(2013). Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity..
J Clin Lipidol. 7(1), 88.
(2013). Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension..
Curr Pharm Des. 19(21), 3766-72.
(2013). The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study..
Curr Vasc Pharmacol. 11(5), 779-84.
(2013). Statins and nonalcoholic fatty liver disease: a bright future?.
Expert Opin Investig Drugs. 22(9), 1089-93.
(2013). The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings..
Arch Med Sci. 8(1), 6-10.
(2012). Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?.
Curr Vasc Pharmacol. 10(3), 374-7.
(2012). Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance..
J Clin Lipidol. 6(1), 93.
(2012). Fibrinogen, hematocrit, and platelets in mild kidney dysfunction and the role of uric acid: an Italian male population study..
Clin Appl Thromb Hemost. 18(1), 113-4.
(2012). Lipid lowering agents and the endothelium: an update after 4 years..
Curr Vasc Pharmacol. 10(1), 33-41.
(2012).
(2012).